Two decades ago, patients lacking circulating serum ceruloplasmin (Cp) presented with neurodegeneration associated with brain iron accumulation. These patients, with mutations in the MCO (multi-copper oxidase), Cp, revealed an essential role for Cp in iron homoeostasis. The patients were diagnosed in adulthood with CNS (central nervous system) disease and progressed rapidly, making understanding the mechanism of disease imperative. We now know that (i) Cp regulates the efficiency of iron efflux, (ii) Cp stabilizes ferroportin membrane expression, (iii) GPI (glycosylphosphatidylinositol)-linked Cp is the predominant form expressed in brain, (iv) Cp functions as a ferroxidase and regulates the oxidation of Fe 2+ to Fe 3+ , (v) Cp does not bind to transferrin directly, and (vi) Cp is one member of a family of mammalian MCOs, which includes hephaestin. It is still unclear how an absence of Cp results in neurodegeneration: is the iron accumulation a primary or secondary injury? Although it is attractive to invoke an iron-mediated oxidative stress mechanism for the neuronal injury and degeneration in aceruloplasminaemia, our data suggest limited redox injury in the brains of mice lacking MCO. In fact, we propose a role for neuronal iron starvation with associated astrocyte and microglial iron overload. With the defect in aceruloplasminaemia being one of inefficient iron efflux from macrophages, we believe that the iron is trapped in a compartment not readily available to participate in oxyradical injury. It is likely that different mechanisms of neuronal cell protection are offered by astrocytes and microglia, and, once these cells are damaged, neuronal survival is compromised.
Introduction
Although for decades it has been clear that iron is an essential nutrient, the exact role for iron in CNS (central nervous system) development and functioning is less well understood. The characterization of the TfR (transferrin receptor)-knockout mouse by Levy et al. in 1999 [1] demonstrated that a gene mutation in the receptor integral for transferrin-bound iron uptake culminated in embryonic lethality associated with profound CNS abnormalities. Iron, it appeared, was critical for brain and spinal cord formation and development. It has now been established that neurons need iron. Iron is a prerequisite for the neurotransmitter synthesis enzymes tyrosine hydroxylase and tryptophan hydroxylase [2, 3] . Iron, incorporated into haem, is the backbone of the mitochondrial electron-transport chain and is essential for cellular metabolism. Neuronal TfR expression reflects neuronal iron demands and is greatest during embryonic development [4] . To accommodate both the critical need for iron and the potential toxicity of this transition metal owing to its potential to generate reactive oxygen species, a complex system of balance has developed. Although iron metabolism is only regulated at the level of absorption, tissue-specific expression of proteins necessary for normal iron homoeostasis provides an additional layer of control.
The importance of this transition metal is underscored by the four separate 'iron cycles' that exist in the body: the 'systemic cycle' (gut, bone marrow and liver), the 'CNS cycle' (retina and brain), the 'placenta cycle' and the 'testicular cycle'. Behind every blood barrier, distinct iron proteins are synthesized: transferrin, DMT1 (divalent metal transporter 1)/SLC11A2 (solute carrier family 11a member 2) and Cp (ceruloplasmin) species [5] [6] [7] iron accumulates with aging and neurodegeneration, set the stage for the discussion of the role of iron in neurobiology and neuropathology. Neurodegenerative diseases, as diverse as Alzheimer's disease, Parkinson's disease, Huntington's disease, aceruloplasminaemia and ALS (amyotrophic lateral sclerosis), share a conspicuous common feature: selective neuronal loss. The mechanism(s) of this neuronal loss and the basis for the selective vulnerability of certain neuron populations is unknown. These diseases also are noteworthy for increased brain iron accumulation. The abnormal accumulation of iron in the brain does not appear to be a result of increased dietary iron, but rather a disruption in the complex process of cellular iron regulation. Whether the iron deposition is a cause or result of the neuronal loss remains to be determined.
Neuronal iron uptake
In order to understand neuronal iron uptake, we must first identify and localize the proteins currently known to play a role in iron homoeostasis. Iron may enter the CNS across two separate membranes: the BBB (blood-brain barrier) and the BCSF [blood-CSF (cerebrospinal fluid)]
interface. The abundant expression of TfR throughout the CNS and specifically on neurons indicates that neurons can acquire iron through the classic transferrin-TfR endocytosis pathway. Presumably, diferric transferrin binds the TfR located in small clathrin-coated pits. At neutral pH, binding of transferrin-Fe 3+ to the TfR is favoured. Through a pH-dependent and anion-dependent process, these 'pits' containing transferrin-Fe 3+ -TfR invaginate into the cells to form endosomes. Upon endosomal maturation, proton pumps adjust the endosomal pH, and iron is released from the transferrin-TfR complex. At acidic pH, the iron is released from the transferrin-Fe 3+ -TfR complex, and the transferrinTfR complex is recycled to the surface, where, at a neutral pH, affinity is low for a transferrin-TfR complex lacking Fe 3+ . Released Fe 2+ , following acidic reduction or STEAP (six-transmembrane epithelial antigen of the prostate) protein ferrireduction from Fe 3+ to Fe 2+ , is trafficked across the membrane via DMT1 [8, 9] . Studies of the Belgrade rat (b/b) revealed that normal DMT1 expression localized to, but was not limited to, neurons, choroid plexus epithelium, ependymal cells and vascular endothelium [10, 11] .
Presumably, iron, as Fe 3+ , bound to transferrin binds to the TfR on the BBB, and iron is endocytosed into brain capillary endothelial cells. The TfR is then recycled back to the bloodstream, while the NTBI (non-transferrin-bound iron) is maintained in the brain capillary endothelial cell. This Fe 2+ would then exit the cell via ferroportin in response to a gradient and be oxidized rapidly by either perivascular astrocytespecific or secreted Cp or other non-specific ferroxidase to Fe 3+ . In the Fe 3+ state, iron binds transferrin that is synthesized by oligodendrocytes and then provides iron to those cells expressing TfRs. Fe 2+ that escapes oxidation is taken up rapidly by an NTBI mechanism. Glial cells lack TfR and have abundant ferritin: they are professional iron-storage cells.
Studies on iron transport in the hypotransferrinaemic mouse (hpx) have revealed that neurons acquire iron via both a transferrin-TfR-mediated endocytosis and an NTBI mechanism [12] . Homozygote (hpx/hpx) mice had an equivalent 59 Fe uptake compared with control and heterozygote (+/hpx) at 24 h following intravenous injection of 59 Fe. Distribution of 59 Fe revealed greater uptake in the hippocampus and cerebellum of the hypotransferrinaemic mice at both 2 and 24 h post-injection, whereas the rate of uptake suggested that brain iron uptake is independent of plasma or tissue transferrin [10] . Further evidence for the critical role NTBI transport has in the CNS has been revealed in that mice engineered to be lacking Slc11A2 (DMT1) are viable, anaemic and without gross CNS defects [6] . Their phenotype suggests that DMT1 is essential for gut and bone marrow iron demands to be met, but that alternative methods of iron delivery take over in the placenta, liver and brain. More recently, oligodendrocyte transferrin synthesis has been postulated as being critical for oligodendrocyte differentiation and myelinogenesis and less important for transferrin-mediated iron uptake. The physiological significance of neuronal NTBI uptake has yet to be determined, as do the mechanisms by which this happens. The ratio of CSF iron to transferrin has frequently revealed will need to determine exact hephaestin localization and its relationship to ferroportin (Fpn) on the neuronal cell membrane. Additionally, ferrokinetic studies will need to be performed to determine whether iron is moving in or out of the neuron with the help of hephaestin. Disrupted NO homoeostasis and excessive Cu + potentially increase oxyradical risk when Cp is lacking. Tf, transferrin. a molar excess of iron, giving more credence to a more significant role for NTBI transport in the CNS.
A final addition to the discussion of neuronal iron uptake requires recognition of axonal iron trafficking as yet another mechanism of iron uptake. Immunohistochemical ferroportin quantification in postnatal rat brain reveals abundant axonal expression, presumably involved in iron homoeostasis [13] . Intra-axonal and retrograde axonal transport of molecules is critical for the regulation of neuronal differentiation and subsequent neuronal survival [14] . Retrograde axonal transport function is altered with aging and results in changes in nutrient delivery in an increasingly more susceptible cell population [15] . Thus it is not surprising that many of the major neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and ALS, display axonal pathologies, including abnormal accumulations of proteins and organelles. Axonal injury may be a primary or secondary component of the illness.
CNS iron homoeostasis
Once iron enters the neuron, it presumably has one of three fates: (i) it enters the cell following transferrin-TfR recycling in an endosome where DMT1 will subsequently export Fe 2+ in to the cytosol; (ii) it enters the cell as Fe 2+ directly into the cytosol; or (iii) in select neurons (globus pallidus, medial habenular nucleus) that make ferritin, it is incorporated into ferritin for storage. Presumably, neurons, astrocytes, other glial and microglial cells utilize iron for biosynthetic functions and store excess iron when they are able. Glia and microglia are capable of storing large amounts of iron, whereas most neurons can only use the iron they acquire immediately. One could propose that neurons are thus more selectively sensitive to changes in iron availability and might be more sensitive to both extremes of iron status: iron toxicity and iron starvation.
Ferroportin, the basolateral membrane iron exporter, has been characterized and expression has been revealed on BBB endothelial cells, neurons, oligodendrocytes, astrocytes, the choroid plexus and ependymal cells. Recently, it has been revealed that Cp is essential for stabilization of ferroportin on the basolateral membrane surface [16] . Therefore, under conditions of Cp deficiency, either as a result of mutations in the Cp gene, genetic defects resulting in a defect in incorporating copper into Cp (Wilson's disease) or severe nutritional copper deprivation, ferroportin is not expressed on the basolateral membrane and results in deceased iron efflux and potentiates cellular iron overload. Although these studies identifying a relationship between Cp and ferroportin were performed with Cp and the yeast homologue Fet3, it is intriguing to speculate that hephaestin may also play an important role as a ferroxidase critical for ferroportin basal lateral membrane localization [16] .
Cp, an MCO (multi-copper oxidase) with ferroxidase activity which facilitates the oxidation of Fe 2+ to Fe 3+ for subsequent binding to transferrin, is both synthesized and secreted by astrocytes as well as predominantly found as a GPI-linked protein on the astrocyte cell surface [17] . It is important to note that the astrocytes that express Cp are those that are most intimately associated with the vasculature. The foot processes of these astrocytes extend great distances and can be localized adjacently to neurons. Additionally, Cp is localized to ependymal cells, the choroid plexus, substantia nigra, Purkinje cells and the granule cell layer of the cerebellum. Hephaestin, the second MCO and Cp homologue, is abundantly expressed in the mouse CNS and is found on neurons, ependymal cells, the choroid plexus, neuronal bodies in hippocampus, corpus callosum oligodendrocytes, glial cell bodies in cortex, substantia nigra (pars compacta), Purkinje cells and the granule cell layer of the cerebellum (Figure 1 ).
MCOs and the CNS
We speculate that the abundant expression of both Cp and hephaestin within the CNS reflects not only the ability of these MCOs to function as ferroxidases, but also their role in superoxide and H 2 O 2 inactivation, as cuprous oxidases and as an NO oxidase/nitrite synthase [18, 19] . Cp functions as a antioxidant in that it maintains redox by oxidizing free Fe 2+ , Cu + and maintaining a nitrite (NO 2 − ) pool, the preferred NO species in deoxygenated ischaemic tissue [18, 19] (Figure 2 ). Whereas it has been proposed that Cp and hephaestin have similar roles as ferroxidases and that their unique tissue specificity determines whether the iron being trafficked is moving in (absorption) or moving out (efflux), numerous examples in the mouse CNS reveal both MCOs present on the same cell. The human disease aceruloplasminaemia results from an absence of Cp as a result of mutations in the Cp gene. Lacking the circulating serum protein and the GPI-linked form of the protein, iron accumulates in the liver, pancreas, retina and brain. Patients present in their fourth or fifth decade of life with varying signs of neurodegeneration. Aceruloplasminaemics have insulin-dependent diabetes as a result of selective β-islet cell loss secondary to iron deposition. Presumably, β-islet cells express DMT1 to facilitate zinc uptake required for insulin synthesis and secretion. Brain regions most affected with neuronal loss are additionally those same regions with most iron accumulation and necrosis: the substantia nigra, caudate nucleus, globus palli dus, putamen and red and dentate nucleus. Both hephaestin and Cp must be lacking in mice for a neurodegenerative phenotype to occur. Although the Cp-knockout mouse, Cp −/− , has increased brain iron and evidence of increased brain lipid peroxidation by 1 year of age, there is no neurodegeneration. Mice generated by crossing the Cp −/− mice with sla −/y mice (hephaestin-knockout, sex-linked anaemia mouse) result in a mouse lacking Cp and with variable low levels of hephaestin. Hephaestin ferroxidase activities vary from 3 to 15% of wild-type. These mice have profound neurodegeneration consistent with the human disease. In mice, hephaestin expression is able to maintain a stable redox environment such that only when both are lacking is a CNS disorder manifest.
The questions remain by what mechanism does a lack of MCOs cause neurodegeneration and is the iron accumulation a primary or secondary event? It is attractive to propose a redox-mediated injury and postulate a disruption in Fenton chemistry with free iron and copper generating OH • radicals and ONOO − (peroxynitrite). However, preliminary data suggest that there is no evidence of oxyradical damage as measured by TBARS (thiobarbituric acidreacting substances) or F 2 -isoprostane values (Figure 3) . In comparing wild-type, Cp −/− , sla −/y and MCO-doubleknockout Cp −/− sla −/y mice, there is no statistically significant difference in any F 2 -isoprostane measurement of direct oxidative damage. In a separate model, the middle cerebral artery occlusion model with a 90 min occlusion and a 3 and 24 h reperfusion, while infarct volume was increased in the Cp −/− mice compared with wild-type mice, there was no statistically significant difference in TBARS generated between the two groups at either time point (Figure 3) .
Although still preliminary, we propose a role for neuronal iron starvation with associated astrocyte and microglial iron overload. It is likely that different mechanisms of neuronal cell protection are offered by astrocytes and microglia, and, once these cells are damaged, neuronal survival is compromised. Free Fe 2+ , Cu + and ONOO − undoubtedly are a part of the damage that occurs. It has been shown that Cp prevents free radical injury in the CNS in mice. Aceruloplasminaemic brains have increased lipid peroxidation and mitochondrial dysfunction, increased levels of malondialdehyde, 4-hydroxynonenals and increased iron. However, neuronal cellular stability is affected by iron deficiency. Furthermore, astrocyte and microglial integrity and function are undoubtedly affected. The next direction will be to dissect the mechanism of neurodegeneration and determine the role of iron deposition in this unique form of CNS pathology, aceruloplasminaemia.
